| Trial | Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS)
ClinicalTrials.gov Identifier: NCT03110432 |
| Aim | Registry study |
| Study design | Prospective observational registry. Patients will receive either standard lipid lowering therapy (statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids and any combinations of these agents), or a PCSK9 inhibitor. The duration of the study is 3 years. |
| Patients | 2000 patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for PCSK9 use, and are treated by office-based cardiologists or in lipid ambulances. |
| Primary outcome | LDL cholesterol goal achievement < 70 mg/dl at 3 years |
| Key results | Ongoing |
| Safety | |
| Author conclusion | |
| Publication | |
| Link | https://clinicaltrials.gov/ct2/show/NCT03110432 |
News
Evolocumab prevents carotid artery wall thickening in paediatric HeFHPCSK9 plays critical role in abdominal aortic aneurysmPost hoc analysis: alirocumab benefits HeFH and T3HLP patientsResults from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acidPCSK9 inhibitors are unlikely to contribute to mood disordersPCSK9 inhibitors may be effective treatment for PAD
